126533-96-8

Basic information

• Product Name: (2-Morpholino-1,3-thiazol-4-yl)methanol
• Synonyms: (2-Morpholino-1,3-thiazol-4-yl)methanol;4-(Hydroxymethyl)-2-morpholin-4-yl-1,3-thiazole;(2-Morpholin-4-yl-1,3-thiazol-4-yl)methanol
• CAS NO: 126533-96-8
• Molecular Formula: C₈H₁₂N₂O₂S
• Molecular Weight: 200.25808
• Mol File: 126533-96-8.mol

Chemical Properties

• Melting Point: 118.5 °C
• Boiling Point: 385.579 °C at 760 mmHg
• Flash Point: 187 °C
• Appearance: /
• Density: 1.341 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.599
• PKA: 13.14±0.10(Predicted)
• CAS DataBase Reference: (2-Morpholino-1,3-thiazol-4-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2-Morpholino-1,3-thiazol-4-yl)methanol(126533-96-8)
• EPA Substance Registry System: (2-Morpholino-1,3-thiazol-4-yl)methanol(126533-96-8)

Safety Data

• Hazard Codes: Harmful:
• Hazardous Substances Data: 126533-96-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(2-Morpholino-1,3-thiazol-4-yl)methanol is used as a research tool for exploring its potential pharmacological properties. Its heterocyclic nature and the presence of the morpholino and thiazole rings may contribute to its biological activity, making it a candidate for further study in the development of new medications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (2-Morpholino-1,3-thiazol-4-yl)methanol is utilized as a compound with potential therapeutic applications. Its structure may allow for the modulation of biological targets, offering a foundation for the design of novel drugs with specific therapeutic effects.
Note: Since the provided materials do not specify particular applications or industries for (2-Morpholino-1,3-thiazol-4-yl)methanol, the uses listed above are general and based on the compound's potential as indicated by its structure and field of interest. Further research would be necessary to identify specific applications and industries where this compound could be utilized.

InChI:InChI=1/C8H12N2O2S/c11-5-7-6-13-8(9-7)10-1-3-12-4-2-10/h6,11H,1-5H2

Upstream product

• 126533-95-7 ethyl 2-(4-morpholinyl)thiazole-4-carboxylate 
• 14294-10-1 morpholinothiourea 
• 862873-20-9 4-(1H-imidazol-1-ylcarbonothioyl)morpholine 
• 1476847-61-6 methyl 2-morpholinothiazole-4-carboxylate 

Downstream Products

• 90842-18-5 2-anilinothiazole-4-carbaldehyde 

Relevant articles and documents

IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION

The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

PAR4 AGONIST PEPTIDES

The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption. Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 μM) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.

RETROVIRAL PROTEASE INHIBITING PIPERAZINE COMPOUNDS

Retroviral protease inhibiting compounds of the formula: STR1 are disclosed.

RETROVIRAL PROTEASE INHIBITING COMPOUNDS

A retroviral protease inhibiting compound of the formula: STR1 is disclosed wherein R 1, R 2, R 5, R 6, Y m and Y' n are herein defined.